Back to discover
Disease

Choroidal neovascularization

Late-stage therapeutic development
15
Clinical trials
4
Associated genes
3
Related proteins

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 3 clinical trials expected to report results, the earliest in Q4 2026.
Upcoming Milestones
Clinical Milestones4View
Results expected 3
Recently completed 1
Activity timeline4

Clinical trials

12 sponsors · 1 new · 1 completed in the last 12 months (net +1)

The current development programme across all trial phases.

Clinical programme
15
All trials
3
Active
13
Late-stage
6
Completed
Late-stage studies

Faricimab Fixed Quarterly Maintenance for Neovascular Age Related Macular Degeneration: A Prospective Case Series

Phase 4 · Recruiting · Hospital Authority, Hong Kong

A Randomized Double-masked, Multicenter, 3-arm, Pivotal Phase 2/3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) EYE201/MK-8748 Compared to Aflibercept (2 mg) in Participants With Neovascular Age-related Macular Degeneration (NVAMD)

Phase 2/3 · Recruiting · EyeBiotech Ltd.

A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants With nAMD (ATMOSPHERE)

Phase 2/3 · Active, not recruiting · AbbVie

A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia

Phase 3 · Completed · Hoffmann-La Roche

Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3)

Phase 4 · Completed · Poitiers University Hospital

A Phase IV, Randomised, Single Masked Study Investigating the Efficacy and Safety of Ranibizumab "Inject and Extend" Using an Intensive Retinal Fluid Retreatment Regimen Compared to a Relaxed Retinal Fluid Retreatment Regimen in Patients With Wet Age-related Macular Degeneration (AMD)

Phase 4 · Completed · Novartis Pharmaceuticals
Recently completed

A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia

Phase 3 · Completed · Hoffmann-La Roche

Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3)

Phase 4 · Completed · Poitiers University Hospital

Dosing Strategy of Intravitreal Ranibizumab for Myopia Choroidal Neovascularization: a Single Center Randomized Prospective Study

Phase 4 · Completed · Zhongshan Ophthalmic Center, Sun Yat-sen University

A Phase IV, Randomised, Single Masked Study Investigating the Efficacy and Safety of Ranibizumab "Inject and Extend" Using an Intensive Retinal Fluid Retreatment Regimen Compared to a Relaxed Retinal Fluid Retreatment Regimen in Patients With Wet Age-related Macular Degeneration (AMD)

Phase 4 · Completed · Novartis Pharmaceuticals

Time Course of Activity Signs at High Resolution OCT During OCT-guided High Frequency Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Age Related Macular Degeneration

Phase 4 · Completed · Vista Klinik

A 12-month, Phase III, Randomized, Double-masked, Multicenter, Active-controlled Study to Evaluate the Efficacy and Safety of Two Individualized Regimens of 0.5mg Ranibizumab vs. Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia

Phase 3 · Completed · Novartis Pharmaceuticals

Associated genes

4 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

VEGFA0.61PGF0.59VEGFC0.28NRL0.12

Disease biology

3 matches

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Vascular endothelial growth factor A, long formvia VEGFA0.61Placenta growth factorvia PGF0.59Vascular endothelial growth factor Cvia VEGFC0.28

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A pathological process consisting of the formation of new blood vessels in the CHOROID.

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.